Overview

Goserelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that acts as a potent GnRH receptor agonist. First approved by the FDA in 1989, it is marketed under the brand name Zoladex for the treatment of hormone-sensitive cancers and reproductive disorders.

The peptide works by initially stimulating, then suppressing the hypothalamic-pituitary-gonadal axis, leading to profound reductions in testosterone and estrogen levels. This mechanism makes it valuable in treating conditions where sex hormone suppression is therapeutically beneficial, including prostate cancer, breast cancer in premenopausal women, and endometriosis.

Goserelin is administered as a biodegradable subcutaneous implant that provides sustained hormone suppression for 1-3 months, offering significant convenience advantages over daily oral medications or frequent injections.

Mechanism of Action

Goserelin functions as a synthetic GnRH receptor agonist with a unique biphasic mechanism of action:

Initial Stimulation Phase (Days 1-7):

• Binds to GnRH receptors in the anterior pituitary with high affinity
• Initially stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release
• Causes temporary increase in testosterone and estrogen levels ("flare" effect)

Sustained Suppression Phase (Days 7+):

• Continuous receptor occupancy leads to receptor desensitization and downregulation
• Pituitary becomes refractory to endogenous GnRH stimulation
• Results in profound suppression of LH and FSH secretion
• Testosterone levels drop to castrate levels (<50 ng/dL) in men
• Estradiol levels fall to postmenopausal ranges (<20 pg/mL) in women

The depot formulation ensures sustained peptide release over 1-3 months, maintaining consistent hormone suppression without daily dosing requirements.

Research Summary

Extensive clinical research supports goserelin's efficacy across multiple indications. Research includes large-scale randomized controlled trials, real-world effectiveness studies, and long-term safety analyses spanning over three decades of clinical use.

Key Studies

Clinical Pharmacokinetics (2000): Comprehensive pharmacokinetic analysis demonstrated biphasic elimination with initial half-life of 2.3 hours and terminal half-life of 4.2 hours. Peak serum concentrations occur 12-15 days post-injection with sustained therapeutic levels maintained throughout the dosing interval.

Real-world Prostate Cancer Study (2024): Large Chinese cohort study (n=1,247) evaluating goserelin 10.8-mg depot in localized/locally advanced prostate cancer showed 94.7% of patients achieved castrate testosterone levels within 6 months, with PSA response rates of 89.3%.

Breast Cancer Ovarian Protection (2015, NEJM): Landmark randomized trial (n=257) demonstrated goserelin significantly protected ovarian function during chemotherapy in premenopausal breast cancer patients, with 22.1% vs 8.2% premature ovarian failure rates (p=0.04).

Three-Month Depot Efficacy (2025): Real-world evidence study confirmed non-inferiority of quarterly 10.8-mg formulation compared to monthly 3.6-mg dosing in U.S. premenopausal breast cancer patients, with equivalent hormone suppression and improved patient compliance.

Pharmacokinetic Microsphere Study (2016): Analysis of PLGA microsphere formulations identified optimal release characteristics preventing peptide degradation and ensuring sustained therapeutic concentrations over extended dosing intervals.

Dosage Guidelines

Goserelin dosing varies by indication and formulation, with depot injections administered subcutaneously into the anterior abdominal wall.

Administration Protocol:

• Inject into subcutaneous tissue of anterior abdominal wall
• Rotate injection sites to prevent local reactions
• No dose adjustments needed for renal or hepatic impairment
• Monthly formulations should be given every 28 days
• Quarterly formulations should be given every 12 weeks

Monitoring Requirements:

• Baseline testosterone/estradiol levels
• PSA monitoring in prostate cancer patients
• Bone density assessments for long-term use
• Liver function tests if clinically indicated
• Cardiovascular risk factor monitoring

Safety Profile

Goserelin demonstrates a well-established safety profile based on over 30 years of clinical use, though side effects are directly related to its mechanism of hormone suppression.

Common Side Effects (>10%):

• Hot flashes and sweating (75-80% of patients)
• Decreased libido and sexual dysfunction
• Injection site reactions (pain, bruising, swelling)
• Mood changes, depression, irritability
• Fatigue and weakness
• Weight gain
• Headache

Serious Adverse Events (<5%):

• Bone density loss and osteoporosis risk with long-term use
• Cardiovascular events (myocardial infarction, stroke)
• Tumor flare during initial treatment weeks
• QT interval prolongation
• Severe allergic reactions (rare)
• Pituitary apoplexy (extremely rare)

Special Monitoring Considerations:

• Bone density monitoring recommended for treatment >6 months
• Cardiovascular risk assessment in elderly patients
• Blood glucose monitoring in diabetic patients
• Depression screening during treatment

Contraindications:

• Pregnancy or suspected pregnancy
• Undiagnosed abnormal vaginal bleeding
• Known hypersensitivity to GnRH analogs
• Severe osteoporosis (relative contraindication)

Stacking

Goserelin is primarily used as monotherapy or in combination with standard cancer treatments rather than peptide stacking protocols.

Oncology Combinations:

• With Radiotherapy: Standard combination for localized prostate cancer, improves progression-free survival
• With Chemotherapy: Used for ovarian protection during breast cancer treatment
• With Antiandrogens: Combined with bicalutamide or enzalutamide in prostate cancer to prevent flare

Supportive Care Combinations:

• Bisphosphonates: Zoledronic acid or alendronate to prevent bone loss
• Calcium/Vitamin D: Standard supplementation during long-term treatment
• Selective Estrogen Receptor Modulators: Raloxifene may help preserve bone density

Not Recommended:

• Combination with other GnRH analogs (redundant mechanisms)
• Use with testosterone replacement (counteracts therapeutic effect)
• Concurrent fertility medications (antagonistic effects)

Timing Considerations:

• Antiandrogen therapy should begin 1-2 weeks before first goserelin injection
• Bone protective agents can be started concurrently
• Supportive medications for hot flashes initiated as needed

References

1. Clinical pharmacokinetics of goserelin. (2000). Clinical pharmacokinetics. DOI PubMed
2. Goserelin. (2006). Nursing times. PubMed
3. Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer. (2024). Cancer biology & medicine. DOI PubMed
4. [Goserelin]. (1990). Ugeskrift for laeger. PubMed
5. [Prostate cancer]. (2006). Nihon rinsho. Japanese journal of clinical medicine. PubMed
6. Goserelin (Zoladex) and the anaemic patient. (1994). British journal of obstetrics and gynaecology. DOI PubMed
7. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women. (2001). British journal of cancer. DOI PubMed
8. Acylation of arginine in goserelin-loaded PLGA microspheres. (2016). European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. DOI PubMed
9. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. (2015). The New England journal of medicine. DOI PubMed
10. Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study. (2025). Breast cancer research and treatment. DOI PubMed